

**The Shifting Landscape of Prescription Drug Abuse: The Canadian Perspective**

International Pre-Symposium

Wednesday, May 15, 2019

**Canada and the Global Mosaic: How Does Prescription Drug Abuse Compare?**

**Janetta L. Iwanicki, MD**

Scientific Director of Research and Surveillance, Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority

**Canadian Approach to Prescription Opioid Risk Management**

**Andrew Slot, PhD**

Manager, Marketed Health Products Directorate, Health Canada

**Cannabis and Opioids: A Cautionary Tale of Cannabis Policies on the Opioid Epidemic**

**Rosalie Liccardo Pacula, PhD**

Director, BING Center for Health Economics; Co-Director, Drug Policy Research Center; Senior Economist; Professor, Pardee RAND Graduate School; RAND Corporation

**Comparing Canada and the United States: The RADARS<sup>®</sup> System**

**Codeine in Canada – Don't Forget Weak Opioids...**

**Beth Sproule, RPh, BScPhm, PharmD**

Centre for Addiction and Mental Health and Leslie Dan Faculty of Pharmacy, University of Toronto

**Emerging Changes in Opioid Diversion in Canada and the United States**

**Mance E. Buttram, PhD**

Associate Director, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University

**Steven P. Kurtz, PhD**

Professor and Director, Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University

**Who's Winning? Opioid Abuse Patterns in the United States and Canada**

**Theodore J. Cicero, PhD**

John P. Feighner Professor of Psychiatry, Department of Psychiatry, Washington University in St. Louis School of Medicine

**Transforming Post-Marketing Surveillance of Prescription Drugs**

13<sup>th</sup> Annual Scientific Meeting

Thursday, May 16, 2019

**Welcome and RADARS<sup>®</sup> System 2018 Data Updates**

**Richard C. Dart, MD, PhD**

Executive Director, RADARS<sup>®</sup> System, Denver Health and Hospital Authority; President, Canadian Consumer Product and Pharmaceutical Safety Inc.

**Project Lazarus: Local Solutions to National Opioid Crisis; What They Need to Know**

**Fred Wells Brason II, Chaplain**

President and CEO, Project Lazarus  
Speaker, U.S. Department of State U.S. Speaker Program, The Bureau of International Information Programs

**The Epidemiology of Prescription Opioid Abuse – A Regulatory Perspective**

**Gerald J. Dal Pan, MD, MHS**

Director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration

**The Dead Speak: How Can Mortality Data Improve Drug Safety?**

**The Evolution of Mortality Data in the United States**

**Richard C. Dart, MD, PhD**

Executive Director, RADARS<sup>®</sup> System, Denver Health and Hospital Authority; President, Canadian Consumer Product and Pharmaceutical Safety Inc.

**Mortality Involving Prescription Drugs**

**Joshua C. Black, PhD**

Associate Research Scientist, Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority

**Lessons from Opana<sup>®</sup> ER: Policy, Behavior, and Reality**

**Janetta L. Iwanicki, MD**

Scientific Director of Research and Surveillance, Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority

**The Route to Utilization of Trend-in-Trend**

**Introduction: Remember Quinoa?**

**John Schwarz, PhD**

Director of Biostatistics, Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority

**Comment: Using Trend-in-Trend to Evaluate Drug Abuse**

**Rose Radin, PhD, MPH**

Epidemiologist, Division of Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, United States Food and Drug Administration

**Next Steps: Evaluating Routes and Comparators**

**John Schwarz, PhD**

Director of Biostatistics, Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority

**Drug Diversion in Healthcare Facilities: Our Nation's Little Secret**

**John J. Burke**

President, Pharmaceutical Diversion Education Inc.  
President and Co-Founder, International Health Facility Diversion Association

## Featured Speakers



**Fred Wells Brason II, Chaplain**

Mr. Brason is a graduate of Dean College. He has served as an innovator, founder, and leader in a number of organizations including: Hospice Chaplain and Hospice Program Coordinator, International Fellowship of Chaplains,

Rank Lt. Colonel, President and Founder of Coastlands Ministries, Affiliate Services Coordinator of National House of Hope and Vice President/Founder and Director of Operations for WillCare, Inc. He has served on the FDA scientific workshop committees for the role of Naloxone in Opioid Overdose Fatality Prevention and Assessment of Analgesic Treatment of Chronic Pain.

Additionally, Mr. Brason Co-Chaired the Expert Committee for the formulation of the SAMHSA Overdose Toolkit, participant on the Roundtable workgroup for the publication of the National Governors Association Opioid Roadmap, also the ASTHO Prescription Drug Misuse and Abuse Strategic Map, serves on the Steering Committee for the American Academy of Addiction Psychiatrists and Project Lazarus has been highlighted in the White House Office of National Drug Control Policy Strategies. Mr. Brason also serves as a speaker in the U.S. Department of State U.S. Speaker Program, The Bureau of International Information Programs. He has published articles in the North Carolina Medical Journal, Wiley Periodicals, the American Journal of Lifestyle Medicine, and the Journal of the North Carolina Medical Board. Mr. Brason received the Robert Wood Johnson Foundation Community Health Leader Award 2012 and has been inducted into their Alumni Network.



**Gerald J. Dal Pan, MD, MHS**

Gerald J. Dal Pan, MD, MHS currently serves as the Director of the Office of Surveillance and Epidemiology in FDA's Center for Drug Evaluation and Research, where since 2005 he has been responsible for the Center's programs in adverse event surveillance

and analysis, pharmacoepidemiology, risk management, and medication error prevention. In this capacity, he is involved in both the premarket and postmarket regulation of drugs and therapeutic biologics, and in the implementation of the drug safety provisions of the Food and Drug Administration Amendments Act and other initiatives. He is a member of the World Health Organization Advisory Committee on the Safety of Medicinal Products, and has served on working groups of the Council of International Organization of Medical Sciences (CIOMS) and the International Council on Harmonisation (ICH). He received his MD from Columbia University College of Physicians and Surgeons and his Master of Health Science in Clinical Epidemiology from the Johns Hopkins University School of Hygiene and Public Health. He completed residency training in Internal Medicine at the Hospital of the University of Pennsylvania and in Neurology at the Johns Hopkins Hospital. He is board certified in both Internal Medicine and Neurology. He joined FDA in 2000 as a medical reviewer in the Center's Office of New Drugs. Before working at FDA, he was a faculty member in the Department of Neurology at Johns Hopkins and worked in the pharmaceutical industry.



**Rosalie Liccardo Pacula, PhD**

Rosalie Liccardo Pacula PhD is a Senior Economist at the RAND Corporation and a Professor at the Pardee RAND Graduate School. She serves as Director of RAND's BING Center for Health Economics, co-Director of the RAND's Drug Policy

Research Center and as Co-PI of RAND's Opioid Policy Tools and Information Center of Excellence (OPTIC). Her research focuses on issues related to illegal or imperfect markets (health care markets, insurance markets, markets for addictive goods), the measurement of these markets, the impact they have on behavior, and the effectiveness of policy interventions at targeting behavior in them. She has applied much of this knowledge to study addiction, addiction policy, and the health care system delivery of treatment for addiction services. She was the lead investigator of several NIH studies examining the impact of cannabis liberalization policies (decriminalization, medicalization and legalization) on use and public health as well as their impact on the use of other substances (alcohol, prescription opioids and heroin) and is currently leading NIH funded research constructed a state-level cannabis policy index and examining the impact of cannabis availability in local markets on medical and non-medical use of cannabis and opioids.



**Rose Radin, PhD, MPH**

Rose Radin is an acting team lead on the Drug Abuse Team in the Division of Epidemiology, Office of Surveillance and Epidemiology, within FDA's Center for Drug Evaluation and Research. Her team is responsible for observational data related to identifying and mitigating the risks

associated with prescription drug abuse. This work includes oversight of post-marketing requirements, Risk Evaluation and Mitigation Strategies, and FDA-funded research, and evaluation of evidence for policy-making. Before joining FDA, Rose's work experience and training focused on prospective cohort studies and causal modeling. She was a postdoctoral fellow at the National Institutes of Health and received her PhD and MPH in Epidemiology from Boston University.

**Andrew Slot, PhD**

Andrew completed his undergraduate degree in Biomedical Toxicology from the University of Guelph, Canada, and both a Masters and PhD degree from Queen's University, Canada, in Physiology and Pathology and Molecular Medicine, respectively. After brief stints as a Quality Assurance officer and Business Development specialist, Andrew joined the Canadian Federal public service in 2012 where he has worked in both the Controlled Substances and Marketed Health Products Directorates in Health Canada. Andrew's experiences as a regulatory scientist have varied from reviewing new psychoactive substances for scheduling purposes to the review of post-market therapeutic product safety issues and product life-cycle risk management.